Associate Director Stone says the injection, while not a cure, “will help reduce the health impact if accidental exposure occurs.“
U.S. Food and Drug Administration (FDA) has approved Xolair (omalizumab) injection for treating IgE-mediated food allergy in certain adults and children aged one year or older. The treatment is intended to reduce allergic reactions such as anaphylaxis, which results from accidental exposure to trigger foods.
Patients must continue avoiding allergenic foods while using Xolair – the medication is not meant for immediate emergency treatment of allergic reactions. Originally approved in 2003 to address moderate to severe allergic asthma, Xolair also gained approval for chronic spontaneous urticaria and chronic rhinosinusitis with nasal polyps in specific patient groups.
“This newly approved use for Xolair will provide a treatment option to reduce the risk of harmful allergic reactions among certain patients with IgE-mediated food allergies,” said Division of Pulmonology, Allergy, and Critical Care Associate Director Kelly Stone. “While it will not eliminate food allergies or allow patients to consume food allergens freely, its repeated use will help reduce the health impact if accidental exposure occurs.”
As the Lord Leads, Pray with Us…
- For Associate Director Stone as she works in the Division of Pulmonology, Allergy, and Critical Care.
- For Commissioner Califf as he oversees the FDA and approvals of medications and therapies.
Sources: Food and Drug Administration
